PDL1 blockade and/or activation of CD40 or 4-1BB pathways into the TME are proven effective ways to enhance the anti-tumor immune response, particularly in combination with OV treatment (Liu et al., 2017; Lu et al., 2022). The gene discussed is TNFRSF9; the disease is neoplasm.